Trials / Completed
CompletedNCT00337155
BAY88-8223, Dose Finding Study in Patients With HRPC
A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223 dichloride (BAY88-8223) | 3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection. |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2008-12-01
- Completion
- 2009-12-01
- First posted
- 2006-06-15
- Last updated
- 2023-11-02
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00337155. Inclusion in this directory is not an endorsement.